White Paper

Perspective Of Aseptic Sampling Product Manager On The PDA Technical Report No. 69

Source: Sartorius

By Charles Meadows

Perspective Of Aseptic Sampling Product Manager On The PDA Technical Report No. 69

Microbial control is a major objective for all sterile drug manufacturers, with bioburden reduction representing a significant share of risk mitigation efforts. The Parenteral Drug Association recently released PDA Technical Report No. 69: Bioburden and Biofilm Management in Pharmaceutical Operations, which provides background on the causes and control strategies of bioburden in pharmaceutical production processes, as well as the risks of biofilm, the challenges of removing it, and strategies to help reduce the incidence of biofilm formation.

The document emphasizes the importance of sampling throughout the process, from upstream manufacturing through downstream purification, culminating in bulk and final filling operations. PDA Technical Report No. 69 strongly suggests the use of aseptic/sterile sampling devices. Alternative sampling methods can lead to false positive results, and can contribute to process fouling by bioburden and biofilm formation.

This paper delves deeper into aseptic sampling devices to explain how they offer superior performance in the effort to control contamination.

access the White Paper!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Bioprocess Online